APx Acquisition Corp. I
APXI
Other OTC11.90
USD
+0.50
- -
CIK
0001868573
ISIN
KYG0440J1094
CUSIP
G0440J109
Return %
Stock
S&P500
1Y
4.39
26.53
3Y
12.90
76.60
5Y
21.06
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kyle Philip Bransfield
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Juan Salvador Agraz 65 Mexico City DF Mexico 05370
- IPO Date
- Jan 28, 2022
- CIK
- 0001868573
- Website
- apxcap.mx
- Similar Companies
- Business
- APx Acquisition Corp. I APx Acquisition Corp. I is a blank check company sponsored by APx Capital Group that focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities, primarily targeting opportunities in Spanish-speaking markets including Latin America or companies providing goods and services to Spanish-speaking communities worldwide; it offers no current products or operational services beyond its SPAC structure for capital deployment and strategic combinations. Founded in 2021 and based in Mexico City with operational ties to Nashville, Tennessee, the company operates globally with a focus on emerging markets in health technology, precision medicine, AI-enabled preventive healthcare, and tech-enabled consumer services. Led by serial SPAC sponsor Kyle Bransfield in partnership with Daniel Braatz and Xavier Martinez, APx Acquisition Corp. I maintains a trust account for investor funds pending a business combination and adheres to Nasdaq listing standards despite prior compliance notices. Recent developments include a March 2024 business combination agreement with OmnigenicsAI Corp. and MultiplAI Health Ltd. to create a global AI-driven genomics platform via reverse merger, which remains pending; an earlier letter of intent with Bioceres Group for a precision medicine diagnostic and wellness services company; shareholder-approved extensions of its initial business combination deadline, most recently to December 9, 2025, accompanied by amendments removing net tangible asset redemption limits and adjusting the investment management trust agreement; and Nasdaq delisting notifications in 2024 for its warrants and units due to low market value alongside efforts to file delinquent reports including the 10-K.
APX Acquisition Corp. I Announces Nasdaq Delisting Notification for Warrants and Units
APX Acquisition Corp. I Reports 10-K Delinquency Notice
APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform
APX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q
APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company